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ABSTRACT
Purpose Medium chain fatty acid salts promote absorption by
increasing paracellular permeability of the intestinal epithelium.
Novel oily suspension (OS) formulation disperses a powder
containing sodium caprylate and macromolecules such as
octreotide or fluorescent dextran (FD). Formulation safety, mac-
romolecule absorption and pharmacokinetic (PK)/pharmacody-
namic (PD) were evaluated.
Methods Octreotide/OS toxicity was evaluated in monkeys fol-
lowing 9 months of daily oral enteric-coated capsule administra-
tion. The OS permeation effect was also assessed in rats, using
FD/OS and octreotide/OS preparations. Octreotide/OS effects
on circulating growth hormone (GH) levels were also measured.
Results Safety assessment of octreotide/OS in monkeys after
9 months showed minor drug-related findings, comparable to
the injectable octreotide. Octreotide exposure levels were similar
across the treatment periods. In rats, OS facilitated FD perme-
ation up to 70 kDa in a reversible, spatial and dose-dependent
manner, independent of the intestinal dosing site. Following OS
administration, the staining pattern of the tight-junction protein,
ZO-1, changed transiently, and a paracellular penetration marker,
LC-biotin, permeated between adjacent epithelial cells. Enteral
octreotide/OS absorption was dose-dependent and suppressed
rat GH levels.
Conclusions Oral octreotide/OS dosing was shown to be safe in
monkeys. OS enhances intestinal absorption of active octreotide,
likely by transient alteration of the tight junction protein complex.
KEY WORDS absorption enhancer . intestinal permeability .






MCFAS Medium chain fatty acids
MLC Myosin light chains
OS Oily suspension





Passive intestinal absorption of hydrophilic macromolecules
such as proteins or peptides (> 3 amino acids) (1) is limited due
to low intestinal permeability and intraluminal enzymatic
degradation (2,3). In contrast, lipophilic molecules are more
likely to undergo passive partition into epithelial cell mem-
branes, and thus be absorbed via a transcellular route (4).
Columnar epithelial cells, joined at the apical surface by the
tight junction complex, serve as an intestinal barrier for
paracellular permeation of water-soluble macromolecules.
The tight junction complex consists of transmembrane pro-
teins, such as occludin and claudins, and several cytosolic
proteins (5,6). Barrier functions are dynamically regulated by
extracellular stimuli that are both physiologic (sugars, amino
acids, and minerals) and pathophysiologic (pathogens and
toxins) (7,8).
The tight junction permeation is enhanced by dietary
components and/or other naturally occurring substances af-
firmed as Generally Recognized As Safe (GRAS) such as-
glycerides, acylcarnitines, bile salts, and medium chain fatty
acids [See review in (9)]. Sodium salts of medium chain fatty
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acids (MCFAS) were also suggested to be permeation en-
hancers. The most extensively studied MCFAS is sodium
caprate, a salt of capric acid, which comprises 2-3% of the
fatty acids in the milk fat fraction (10). To date, sodium
caprate is mainly used as an excipient in a suppository formu-
lation (Doktacillin™) for improving rectal ampicillin absorp-
tion. The permeation properties of another dietary MCFAS,
sodium caprylate (8-carbon), were shown in vitro to be lower
when compared to sodium caprate (11–14). In the present
investigation, sodium caprylate and macromolecules viz.,
octreotide, a peptidic drug (15), or dextran, a polysaccharide,
were formulated in an admixture with other excipients in oil
to generate an oily suspension (OS).
This study explored the safety of the novel OS in a
Cynomo l g u s monk e y c h r on i c t o x i c i t y s t u d y .
Pharmacokinetic (PK)/pharmacodynamic (PD) effects of the
OS on peptide or polysaccharide molecules and the OS effect
on intestinal cells were also investigated in a rat model.
MATERIALS AND METHODS
Study Treatments
Formulation of Powder in Oily Suspension
OS (TPE™; Chiasma, Jerusalem, Israel) was prepared using
sodium caprylate as illustrated in Fig. 1 (16,17). Briefly, sodi-
um caprylate (Merck, Darmstadt, Germany) and polyvinyl
pyrrolidone (PVP; Kollidon 12, BASF, Burgbernheim,
Germany) with or without octreotide acetate (Bachem,
Torrence, CA) or fluorescein isothiocyanate (FITC)-labeled
dextran (Sigma, St. Louis, MO) were solubilized in water,
milled (particle size ranging 90 – 100 μm), lyophilized, and
suspended in lipophilic medium consisting of polysorbate 80
(PS 80; Croda, UK), glyceryl monocaprylate (GMC; Abitec,
Janesville, WI) and glyceryl tricaprylate (GTC; Abitec). The
formulated OS was subsequently filled into hard-shell gelatin
capsules (Capsugel, Bornem, Belgium) that were banded with
prewarmed gelatin and 1% Twin 20 solution using a Dott
Bonapace & Co. (Milan, Italy) semi-automatic banding ma-
chine, and dried at room temperature. The OS capsules were
next enteric coated with a 20% aqueous suspension of Acryl-
EZE® (# 93018509; Colorcon, Dartford, UK) using a perfo-
rated coating pan system (Compu-Lab, Thomas Engineering
Inc., Hoffman Estate, IL) to reach a 90 mg capsule weight
gain. The capsules were stored refrigerated (2 to 8°C) prior to
their use.
The octreotide/OS capsules were tested for physical ap-
pearance, potency (assay), dissolution, microbiological and
water content tests before their release and during the chronic
toxicity study under refrigerated (2 to 8°C) and controlled
room temperature (25°C and 60% relative humidity) condi-
tions. The capsules appearance, white matt coated capsule,
was maintained throughout the entire stability period. The
octreotide content in the octreotide/OS capsules was ana-
lyzed by HPLC using Waters Alliance 2695 XE (Waters
Corp., Milford, MA) equipped with Waters Photodiode
Array Detector 2996 at λ=210 nm. Briefly, the capsules were
dissolved in 65 mM ammonium sulfate solution and analyzed
byHPLC, using a C18 column (YMCCo., Ltd. Kyoto, Japan,
4.6×150 mm, 3 μm) with the following mobile phase: water
(A), acetonitrile (B), 0.1% phosphoric acid and 20 mM
sodium-1-decane sulfonate (C). The reported values were
based on the signal area at the appropriate retention time.
The octreotide content in the refrigerated octreotide/OS
Fig. 1 An oily suspention
formulation of powder in lipophilic
medium. Active pharmaceutical
ingredient (API; e.g. octreotide
acetate) was solubilized with
sodium caprylate and polyvinyl
pyrrolidone (PVP) in water. Next,
the solution was milled, lyophilized
and dispersed in lipophilic medium,
comprised of polysorbate 80 (PS
80), glyceryl monocaprylate
(GMC), and glyceryl tricaprylate
(GTC). Drug/oil suspensions are
then filled in capsules which are then
enteric coated.
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capsules confirmedwith the drug specifications over the 9-month
period. In addition, the drug release profiles from the enteric
coated octreotide/OS capsules were carried out using a USP-II
apparatus (Caleva 8ST dissolution apparatus, GB Caleva,
Dorset, England) with a two-stage dissolution method according
to USP <711> and Ph. Eur. 2.9.3. The tests were conducted in
hexaplicates, in 900 ml dissolution medium maintained at 37±
0.5°C. A paddle speed of 50 rpmwas employed. The tests consist
of a 2-h acid stage dissolution in 0.1 N HCl (pH 1.2) with two
sampling time points, and a 1-h buffer stage dissolution in pH 6.8
phosphate buffer with five sampling time points. The medium
was changed by the analyst from the acid to the buffer after the
first stage had been completed. The dissolution aliquots were
withdrawn from the dissolution bath at the indicated time points
and analyzed using the HPLCmethod for octreotide quantifica-
tion. Samples were analyzed with a Phenomenex Luna C18
column (Phenomenex Co., Torrance, CA, 3.0×150 mm,
5 μm) at a flow rate of 0.6 mL/min andmobile phase containing
acetonitrile-water-trifluoroacetic acid using Waters Alliance
2695 XE equipped with Waters Photodiode Array Detector
2996 at λ=220 nm. Again, comparable dissolution profiles
(Fig. 2) were obtained for the refrigerated octreotide/OS cap-
sules during the 9-month period.
Animal Treatments
Enteric-coated capsules containing octreotide (20 mg)/OS or
olive oil were administrated daily per os to fasted monkeys for
9 months, and swallowed with 10 mL water. In addition, a
1 mL ampule containing octreotide acetate at a concentration
of 0.1 mg/mL (Sandostatin®, Novartis Pharmaceuticals, East
Hanover, NJ) was administered by daily subcutaneous (SC)
injection to another monkeys group. Oral administration of
OS in rodent studies was limited due to the lack of properly
enteric coatedmini-gelatin capsules. Thus, theOS, containing
fluorescent marker molecules (see below) or octreotide was
enterally injected via implanted cannulas.
Animals
Monkeys
Captive-bred, colony-raised, naive male and female
Cynomolgus monkeys (Macaca fasicularis) were obtained from
Covance Research Products, Inc. (Denver, PA) and acclimated
for 9 days prior to treatment. In compliance with Good
Laboratory Practices (GLPs), monkeys were housed individually
in suspended stainless-steel cages. Room temperature was con-
trolled to 18 – 29°C, humidity to 30% – 70%and cycled lighting
(12 h of light daily). Prior to initiation of the study, the monkeys
were in good health, and free of internal parasites and tubercu-
losis. Certified primate diet (Lab Diet # 5408 Primate Diet, PMI
Nutrition International, Inc, Brentwood, MO) was provided
twice daily (unless otherwise specified) on a feeding regimen of
six to eight biscuits, supplemented by fruits (up to 5 per day).
Water was provided ad libitum. Analysis for specific pathogenic
microorganisms and contaminants showed no significant
findings.
The study was carried out in an Association for the
Assessment and Accreditation of Laboratory Animal Care
International (AAALAC) accredited facility and in compli-
ance with the Animal Welfare Act regulations (9 CFR 1). All
aspects of this study were conducted in accordance with the
Environmental Protection Agency and FDA based upon
Good Laboratory Practice Regulations, 40 CFR 792.
Rats
Intestinal permeability experiments were performed in vivo
using adult male albino Sprague–Dawley (SD) rats (300–
400 g bodyweight), obtained from Harlan (Jerusalem, Israel)
and acclimatized for 1 week in controlled temperature (22±
3°C) and 12-h light and dark cycles. Animals were housed
individually, allowed access to rat chow (2018SC Harlan
Teklad, Madison, WI) and tap water ad libitum. Animals were
fasted for 16 to 18 h overnight before the start of the exper-
iment, between 0700 and 0900 h. Study protocols and proce-
dures were approved by the National Council for Animal
Experimentation, Ministry of Health, Jerusalem, Israel.
Chronic Toxicity Study in Cynomolgus Monkeys
Tissue Sampling and Preparation
At study initiation, monkeys weighing 3.34– 6.24 kg were
randomly assigned (5/sex/group) to daily administration of
Fig. 2 In vitrodissolution profile of enteric-coated gelatin capsules with 20mg
octreotide acetate and oily suspension. The in vitro release rate of octreotide
from floating octreotide/OS enteric-coated capsules (n=6) was determined
using United States Pharmacopeia (USP) Dissolution testing apparatus II (two-
stages, paddle method). Cumulative percentage of the octreotide release was
calculated using an equation obtained from a standard curve.
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single octreotide/OS capsule or control olive oil (negative
control) by intragastric intubation or to SC injection of
octreotide acetate (positive control) for 9 months. During the
dosing period, animals were fasted for 8 to 10 h prior to
dosing, and the first feeding was given 2 h after dosing.
Monkeys were observed twice daily for mortality, morbidity,
and clinical signs of adverse health effects and qualitative food
consumption. Weekly examinations were performed on each
animal before drug administration and before terminal sacri-
fice. Pre-dose body weights were recorded (week −1) and
weekly thereafter. Blood samples (~5 ml) were collected for
hematology and serum chemistry from the femoral vein be-
fore drug administration and from surviving animals prior to
the terminal necropsy.
A complete ophthalmic examination was performed on
each monkey by a Diplomat of the American College of
Veterinary Ophthalmologist veterinarian before animal
selection/group assignment (pretest) and again, prior to study
termination.
Electrocardiograms (ECGs) were obtained twice pre-study
and were analyzed by a veterinary cardiologist for the pres-
ence of significant abnormalities. ECGs were also obtained
following the 1st dose and at the 3, 6, and 9 months of dosing.
Standard ECGs (10 Lead) were recorded at 50 mm/s. Using
Lead II (or another appropriate lead), the RR, PR, and QT
intervals, and QRS duration were measured and heart rate
was determined. The QT interval was calculated using
Bazett’s Rule.
On the 270th day, the monkeys were fasted overnight,
weighed on the followingmorning, and bled for required tests;
then exsanguinated, necropsied, and examined for gross al-
terations. Animals were euthanized with intravenous keta-
mine sodium pentobarbital solution. Exsanguination was
achieved by severing the femoral vessels.
Toxicokinetics
On Day 1 and after 3, 6 and 9 months, whole-blood samples
(3.0 mL) were collected at routine intervals after completion of
oral octreotide dosing. Plasma octreotide levels were deter-
mined by a validated liquid chromatographic spectrometric
method (PPD Laboratories, Richmond, VA) as described
elsewhere (18). The maximum plasma concentration (Cmax)
and time to Cmax (Tmax) were derived from the data. The
area under the curve (AUC) from zero to the last sample with
a concentration ≥LOQ [AUC(0-t)] was calculated using the
linear trapezoidal method. Analysis of plasma octreotide con-
centration vs. time was performed using SAS® for Windows®
Version 9.3. The primary pharmacokinetic end point vari-
ables (Cmax and AUC0-t) were compared using analysis of
variance (ANOVA) with treatment time (1, 180, 270-d) as a
within-subject (repeated measures)-factor and sex as a
between-subject factor.
In Vivo Intestinal Permeability Assay
Intestinal paracellular permeability was determined by mea-
suring the appearance, in the circulation, of a fluorescence
marker, 4.4 kDa FITC-labeled dextran (FD4; Sigma). The
assay of intestinal paracellular permeability was slightly mod-
ified from previously described methods (19–21). Briefly, im-
plantation of jugular venous and intestinal catheters was car-
ried out in SD rats under anesthesia, induced by intraperito-
neal (i.p.) injection of ketamine hydrochloride (Kepro,
Deventer, Holland) at 95 mg/kg bodyweight and xylazine
hydrochloride (Sedaxylan; Eurovet Animal Health BV,
Bladel, Holland) at 9.5 mg/kg bodyweight. Implantation of
the catheters was carried out 5-7-days prior to the experi-
ments. A thin heparinized polyurethane-based elastomer
catheter (Micro-Renathane® MRE 025, 0.305 mm×
0.635 mm; Braintree Scientific Inc., Braintree, MA) was
inserted via a 1-cm longitudinal skin incision, ventrally along
the midline of the neck, into the right jugular vein. The
proximal jejunum was localized immediately caudal to the
ligamentum duodenocolicum, via a 2-cm ventral midline inci-
sion, and a silastic tubing (0.762 mm×1.651 mm; Degania
Silicone Co. Ltd, Degania Bet, Israel) tippet was inserted via
enterotomy to the jejunum. Further experiments involved
implanting an additional thin silastic tubing (0.500 mm×
1.000 mm; Degania Silicone) into the jejunum, adjacent to
the 0.762 mm cannula. In a single series of experiments, a
silastic catheter was inserted 2 cm distal to the pylorus
(duodenum), 5 cm proximal to the cecum (ileum) or 1 cm
distal to the cecum (colon). Both jugular and intestinal cathe-
ters were subcutaneously tunneled, exteriorized behind the
animal shoulder blades and glued (histoacryl glue; B. Braun,
Melsungen, Germany). Catheters were subsequently filled
with heparinized saline and sealed. At the end of the surgery,
all skin openings were closed with 0.5 silk sutures and stainless-
steel wound clips.
For intestinal permeability experiments, 0.3 mL saline or
OS containing 1.65 mg of FD4 was injected via the intestinal
cannula into the lumen of conscious non-restrained rats. OS
effect on permeability was also tested by administration of OS
and fluorescent dextran using two jejunal cannulas, in which
these marker molecule solutions in saline served as a “bystand-
er” to the OS permeation activity. Additionally, in a single
series of experiments, FITC-labeled dextrans of different mo-
lecular weights (average 10, 20, 40 and 70 kDa; Sigma) at an
equivalent dose served as the permeability markers. Baseline
blood samples (500 μL) were collected from the indwelling
jugular catheter pre-dose, and at the indicated times. Blood
was centrifuged at 4°C, 3,000×g for 10 min, and the plasma
was separated for the analysis of FITC-dextran concentration.
Plasma was diluted 1:1 with 5% sodium bicarbonate solution
(Biological-Industries, Beit Haemek, Israel) in duplicate, and
fluorescence intensity of the diluted plasma measured using a
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fluoro-spectrophotometer plate reader (Victor Wallac 1420
Multi-label; Perkin Elmer, Wellesley, MA) with an excitation
wavelength of 485 nm and an emission wavelength of 520 nm.
Plasma FITC-dextran levels are presented in arbitrary fluo-
rescent units (AU).
Immunohistochemistry
Experiments were conducted in anesthetized SD rats, using a
ketamine-xylazine mixture administered i.p., and animals
were kept on warming pads (Bair Hugger®, Augustine
Medical Inc, Eden Prairie, MN) to maintain body tempera-
ture at 38°C. The peritoneum was opened by midline incision
and the proximal jejunum identified. After washing the intes-
tines with 2 mL pre-warmed (37°C) saline solution, 0.3 mL
saline solution or OS was injected 3 times (0, 10- and 20-min)
into the animal lumen. At the indicated time-point, approxi-
mately 1-cm of the intestinal section was removed and washed
with ice-cold phosphate-buffered saline (PBS).
Frozen sections of jejunal tissues were fixed with 4% parafor-
maldehyde in PBS for 2 h at 4°C, and then washed thrice with
ice-cold PBS for 5 min. Next, jejunal sections were incubated
with 30% (wt/wt) sucrose overnight in PBS at 4°C. Jejunal tissues
were embedded in OCT cryostat freezing medium compound
(Electron Microscopy Sciences, Hatfield, PA), snap-frozen in
liquid nitrogen, cryostat sectioned (−80°C) at 14 μm, then
mounted on Superfrost/Plus (Menzel Glaser GMBH,
Braunschweig, Germany) microscope pre-coated slides.
Sections were incubated with monoclonal rabbit antibody
against zonula occludens-1 (ZO-1; Zymed Laboratories Inc.,
San Francisco, CA) and against claudin-3 (Invitrogen
Corporation, Carlsbad, CA) diluted at 1:100 in PBS/0.1%
Tween-20 (PTW) for 72 h at 4°C. After washing thrice in
blocking solution [Tween 20 (2%), heat inactivated goat se-
rum (10%; Biological Industries, Kibbutz Beth Haemek,
Israel) and PBS] for 5 min, sections were incubated with
secondary Alexa Fluor 555-conjugated goat anti-rabbit IgG
antibody (Invitrogen) at 1:200 for 1 h at 4°C. After washing
thrice in blocking solution, sections were mounted on cover
slides and images obtained using a laser-scanning confocal
microscope (Zeiss LSM 510/Axiovert 100 M, Jena,
Germany) and oil immersion objective (×40; NA 1.25).
Rat jejunal sections were also treated with sulfo-NHS-LC-
biotin (Pierce, Rockford, IL) mixed with saline orOS and then
washed, frozen and sectioned in a comparable procedure.
Non-specific binding sites were blocked with blocking solution
and 1 μg/mL non-labeled streptavidin (Zymed) was added for
1 h at room temperature. Sections were incubated for 30-min
with 10 μg/mL of AlexaFluor-633 conjugated streptavidin
(Invitrogen) in blocking solution. After washing thrice in
blocking solution, sections were again incubated with the
blocking solution and 1 μg/mL non-labeled streptavidin.
Sections were then stained for actin by incubation with
Alexa Fluor 555 Phalloidin (Invitrogen) diluted at 1:100 in
the blocking solution for 30-min at 37°C. After washing thrice
in blocking solution, sections were mounted on cover slides
and images obtained using confocal microscopy.
Immunoassays
Octreotide and growth hormone (GH) concentrations were
assayed in rat plasma samples, following intra-jejunal dosing
of 0.3 mL saline or octreotide/OS to cannulated rats.
Octreotide acetate in saline was also injected subcutaneously
to this animal model.
The octreotide immunoassay is based on a single-step,
extraction-free, simultaneous assay procedure (Peninsula
Laboratories, Division of Bachem, San Carlos, CA) designed
to quantify octreotide concentrations. Briefly, octreotide stan-
dards (0.05–6.25 ng/mL) and rat plasma samples were diluted
1:10 with PBS, followed by addition of octreotide anti-rabbit
antiserum antibody, biotinylated octreotide tracer, and assay
buffer. Samples were washed and incubated with
streptavidin–HRP. Optical density was read at a dual absor-
bance of 450 nm and 630 nm using an Enzyme-Linked
Immunoassay (ELISA) reader (Multiskan EX Labsystems;
Thermo Electron Corporation, Milford, MA) after addition
of TMB solution and acidic stopping solution.
Plasma GH was measured by ELISA kit according to the
manufacturer’s instructions (Diagnostic Systems Laboratories,
Webster, TX).
Data Analysis
Results were expressed as mean ± SE. The area under plasma
concentration–time profile measured from time zero to the
last measurable plasma concentration was calculated accord-
ing to the linear trapezoidal rule. Relative enteral bioavail-
ability (rBA) following intra-jejunal administration of the OS





Data were analyzed using ANOVA and a post hoc com-
parison between groups was conducted using the Student’s t-
test (GraphPad, Inplot, SanDiego, CA). A significance level of
P<0.05 was used for all statistical analyses.
RESULTS
Safety Evaluation of Oily Suspension
The effect of oral octreotide/OS administration on animal
safety was evaluated in a 9-month toxicology study in
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Cynomolgus monkeys. No signs of toxicity were observed in
the monkeys during and following daily administration of
octreotide/OS for 9-months. Daily oral dosing of enteric
coated OS-filled capsules with octreotide acetate for 9 months
had no effect on bodyweight, electrocardiogram, ophthalmo-
logical, hematological (including coagulation), or clinical pa-
thology (including Troponin I). Target organ toxicities based
on macroscopic and/or histopathological analyses were not
observed (data not shown). In the chronic study, increased inci-
dence of sparse hair and red discoloured skin was observed in
both sexes as well as a higher incidence of watery feces in the
animals dosed with oral octreotide/OS and injectable
octreotide acetate (positive control), compared to the negative
control group (olive oil). Similar results were reported for the
injectable octreotide formulation in the approved product
label (Novartis, March 2012).
No treatment-related mortality was recorded in this toxi-
cology study; however, three monkeys were euthanized or
found dead (2 male negative control and 1 female positive
control). These cases were attributed to complications in dos-
ing procedures and are treatment-independent. More specif-
ically, the olive oil capsule administration procedure in the
negative control group, i.e. intragastric intubation, resulted in
laryngeal obstruction with dosing capsule (n=1) and pharyn-
geal swelling/thickening and hemorrhage (n=1). In the posi-
tive control, accidental injury following octreotide injection
resulted in fractured humerus and death. One female monkey
from the negative control group was removed from the study
due to a confirmed pregnancy. Thus, additional two animals
were added later to this control group on Day 57.
No morbidity or mortality was documented following sin-
gle or multiple OS dosing to a total of 284 conscious non-
restrained cannulated SD rats.
Oil Suspension Alters Intestinal Permeation In Vivo
Fluorescent marker (FITC-labeled dextran of 4.4 kDa; FD4)
was solubilized in saline solution without or with sodium
caprylate, or formulated with sodium caprylate in OS at a
similar dose (1.65 mg). As expected, negligible increases in
plasma FD4 levels were observed following administration of
FD4 in saline to cannulated SD rats (Fig. 3a). However,
significant increases in plasma FD4 levels were shown follow-
ing dosing of a saline, FD4 and sodium caprylate solution to
rats. An additional 5-fold increase in plasma fluorescent dex-
tran levels was observed after administering formulated FD4
and sodium caprylate in OS. Addition of different FD4 con-
centrations into the OS (Fig. 3b) resulted in a dose-dependent
effect on plasma levels. Dosing FD4/OS at a constant con-
centration and at increasing volumes (Fig. 3c) did not affect
plasma FD4 levels. To examine effects of the molecular size on
absorption, FITC-labeled dextrans of increasing sizes (4 –
70 kDa) were administered to rats concomitantly with OS.
As demonstrated in Fig. 3d, elevation in plasma fluorescent
dextran levels were shown to be inversely correlated with
dextran size and insignificant permeating was detected at
70 kDa. Only low plasma fluorescent dextran levels were
observed in all treated rats with the FITC-labeled dextran
molecules solubilized in saline, irrespective of the molecular
size of the administered marker.
To determine the duration of OS-induced tight junction
permeation, change in plasma FD4 levels were compared in
dosing of FD4 formulated in OS and co-administration of
FD4 in saline and OS from two adjacent cannulas to SD rat
jejunum (Fig. 4a). Both cases resulted in reversible FD4 ab-
sorption; however, formulated FD4/OS [AUC (0–90) 164±
14 AU] elicited a significantly higher elevation in plasma FD4
levels compared with levels observed with co-administration
of FD4 and OS [AUC (0–90) 98±20 AU; P=0.021]. To
examine the duration of permeation enhancement induced
by a single dose of OS, administration of FD4 in saline 10, 30
and 60 min after the OS dosing (Fig. 4a) resulted in a signif-
icant and progressive reduction in FD4 plasma levels [10-min:
AUC (0–90) 64±15 AU, 30-min: AUC (0–90) 20±3 AU, 60-
min: AUC (0–90) 8±1 AU; P<0.001]. The limited FD4
absorption, upon dosing in saline 60-min after OS adminis-
tration, may suggest that OS induces a transient intestinal
permeation of about 1 h duration.
OS-induced permeation effect was tested for reproducibil-
ity over a short time period. Enhanced FD4 absorption was
compared between a single and repeated (3-times) adminis-
tration of FD4 formulated inOS. Figure 4b shows that plasma
FD4 levels after administration of three consecutive FD4/OS
doses, given every 10-min, was 2.6-fold higher (P=0.007) then
after a single dose [AUC (0–90) 90±19 AU and AUC (0–90)
35±7 AU, respectively]. The effect of OS was compared with
administration of FD4/OS to the stomach (via gavage), the
Fig. 3 Permeability of FITC-labeled dextrans across the rat intestines. Plasma
concentrations of fluorescein isothiocyanate (FITC)-labeled ~4.4 kDa dextran
(FD4) were measured during 90-min in cannulated rats (a) following intra-
jejunal administration of 1.65 mg FD4 in (i) saline, (ii) sodium caprylate in saline
solution or (iii) in oily suspension (OS; Data represent Mean ± SE; n=6–10).
FD4 permeability was shown to significantly differ (P<0.0001) between
groups. (b) Rats were dosed with increasing concentrations of FD4
formulated in OS (0.3 mL). Data (Mean ± SE; n=6) represent plasma FD4
area-under-the-plasma concentration time curve normalized to volume
(AUC/volume; squares) and Cmax (circles). (c) A constant dose of FD4,
formulated in increasing volume of OS (0.1, 0.15, 0.2, 0.3 and 0.4 mL)
was administered to cannulated rats and plasma FD4 AUC (squares) and
Cmax (circles) were plotted (Mean ± SE; n=6-12). (d) Dextrans of increasing
sizes FITC–dextran (FD) at 4.4, 10, 20, 40 and 70 kDa were solubilized in
saline and concomitantly administered with OS (gray bars) or without OS
(black bars) to cannulated rats and dextran levels in plasma measured. Bars
represent means (± SE) AUC in arbitrary units (AU) over 90 min period of
permeating experiments in 6–10 animals. Absorption of labeled dextrans, co-
administered with OS, was significantly (P<0.0001) higher than the
absorption of FD dosed without OS.
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small and the large intestines of cannulated SD rats (Fig. 4c).
Enhanced FD4 absorption after formulation in OS differed
Fig. 4 Duration of oily suspension-induced enteral absorption of FD4 in rats.
The effect of oily suspension on intestinal permeability in cannulated rats was
assessed by plasma 4.4 kDa FITC dextran (FD4) concentrations. (a) FD4
plasma concentration-time profiles upon enteral administration of FD4 for-
mulated with oily suspension (OS; dotted line) or co-administered of FD4 in
saline solution with OS (arrow) using adjacent jejunal catheters or FD4 dosing
after 10-, 30- and 60-min (arrowhead) from the OS administration (Mean ±
SE; n=6–10). Plasma FD4 levels were shown to differ (P<0.0001) between
groups, using one-way ANOVA. (b) Intestinal permeability (plasma FD4) after
a single or repeated (arrows) FD4 formulated in OS administration over 30-
min experimental period was shown to be significantly different (P=0.007;
Mean ± SE; n=6–10). (c) Apparent permeability across the rat digestive
system (Mean AUC over 90-min ± SE; n=6–10) of a single dose of FD4/OS
via gavage to the stomach, or via catheter implanted at the duodenum,
proximal jejunum, ileum and colon (See text for details). FD4 absorption
was compared between groups using one-way ANOVA followed by post-
hoc Tukey–Kramer pairwise comparison. Plasma FD4 levels differed
(P<0.0001) between groups, and post hoc analysis revealed that FD4
absorption in the stomach was lower (P<0.05) compared with the duode-
num, jejunum, ileum and colon groups.
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(P<0.001) across the gastrointestinal tract. Post-hoc analysis
suggested that FD4 absorption was significantly lower follow-
ing gavage administration, whilst no differences in FD4 ab-
sorption were detected between the small and the large
intestines.
Effects of theOS formulation on the tight junction complex
were next assessed using an immunohistochemical approach.
The morphological changes of ZO-1, a tight junction protein,
were evaluated by an immunofluorescent antibody labeling
assay. As shown in Fig. 5a, ZO-1 was localized to the epithelial
tight junctions in the jejunum of anesthetized control rats,
which is appreciated as a series of bright red spots at the apical
compartment of cell-cell junctions. In contrast, the ordered
appearance of ZO-1 was altered in the jejunum of rats from
the OS group. Specifically, 1 min following OS administra-
tion, the ZO-1 staining pattern was diffused through the
luminal enterocyte membranes. The ZO-1 staining pattern
of red spots was reestablished within 120 min from OS ad-
ministration (Fig. 5c). Similar observations were shown for
claudin-3 staining pattern prior to and following OS admin-
istration (data not shown). The effect of OS on the intestinal
epithelium was further evaluated using sulfo-NHS-LC-biotin
as a diffusion tracer according to the principle outlined in
Fig. 6a. Images of control rat jejunum indicated that biotin
diffusion tracer accumulated at the lamina propria (Fig. 6b).
In contrast, in the OS group the tracer permeated through the
intestinal barrier and was evident between the epithelial cells
(Fig. 6c).
Pharmacokinetics/Pharmacodynamics of Octreotide
Formulated in Oily Suspension
The toxicokinetics of circulating octreotide were studied fol-
lowing repeated oral administration of octreotide/OS in
enteric-coated capsules to Cynomolgus monkeys in a 9-
month toxicity and toxicokinetic study. Specifically, plasma
samples for measurement of octreotide were collected prior to
and up to 6 h following octreotide/OS or control olive oil
capsules administration. Plasma octreotide concentrations
were below the assay detection limits in the control animals
(data not shown). Monkeys treated with octreotide/OS, howev-
er, exhibited significant plasma exposure to the investigational
drug. Table I depicts the toxicokinetics of circulating
octreotide following the 1st day and after 6- and 9-months
of repeated daily oral octreotide/OS dosing. There was a
consistent, though variable, exposure to octreotide during
the 9 month study period, which was comparable in both
male and female monkeys. The plasma octreotide levels after
oral octreotide/OS capsule (20 mg octreotide) administration
after the 1st day, 6- and 9-months (Table I) were comparable
to the measured plasma octreotide levels after SC injection of
octreotide acetate [0.1 mg; AUC (0-t) Day 1: Males 41.7±
8.6 h×ng/mL, Females 64.3±5.3 h×ng/mL, Day 180:
Males 46.2±5.4 h×ng/mL, Females 60.8±6.9 h×ng/mL,
Day 270: Males 51.3±11.3 h×ng/mL, Females 49.6±
3.0 h×ng/mL; average rBA of 2.3%]. The PK of
octreotide/OS formulation was also evaluated in cannulated
SD rats. Enteral dosing of octreotide acetate in saline solution
resulted in negligible changes in rat plasma peptide concen-
trations (data not shown). Figure 7a shows the mean plasma
concentration-time profile following a single intra-jejunal ad-
ministration of octreotide/OS and after SC injection of
octreotide acetate solution. After enteral administration of
octreotide/OS, plasma octreotide levels rose rapidly, peaked
after 6 min from dosing, and then fell below the limit of assay
quantification after 90 min. Plasma octreotide levels after
enteral octreotide/OS dosing [AUC (0–90) 14.6±
1.4 min×μg/mL] were comparable to levels observed after
SC injection of octreotide acetate [AUC (0–90) 12.3±
0.4 min×μg/mL; average rBA of 7.4%]. Plasma octreotide
concentrations after a single enteral administration of approx-
imately 15, 30 and 50 mg/mL octreotide formulated in OS to
conscious rats were dose proportional (Fig. 7b) for both the
octreotide AUC vs. time as well as maximal plasma levels
achieved.
The PK/PD relationship of octreotide/OS was investigat-
ed in cannulated rats administered intra-jejunal octreotide/
OS or saline, and plasma octreotide and GH concentrations
were determined (Fig. 7c). Octreotide PK parameters were in
agreement with the aforementioned observations in rats. The
Fig. 5 The oily suspension formulation induced transient reorganization of tight junction protein ZO-1. Frozen sections of SD rats proximal jejunumwere labeled
for ZO-1 (red) after 1 (a, b) and 120 (c) minutes from intra-jejunal administration of saline (a) or oily suspension (OS) (b and c). ZO-1 was stained at the apical
junctions in jejunum from saline-treated rats, but presented with an altered staining pattern a minute after intra-jejunal OS dosing. At 120 min post OS
administration, ZO-1 staining pattern was similar to that of saline treated rats. Data are representative of three independent experiments. Scale bar=10 μm.
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time course of GH suppression in the octreotide/OS group
was rapid and significant, as compared with pre-dose GH
levels as well as with levels in the control saline group
(Fig. 7c). GH suppression in the octreotide/OS group was
sustained for >2 h after octreotide levels in plasma were low,
i.e. below the detection limits.
DISCUSSION
Enteral absorption of hydrophilic macromolecules under phys-
iological conditions is restricted by the intestinal epithelium and
especially its tight junctions. Thus, diverse permeation en-
hancers have been extensively studied as adjuvants for oral
delivery of macromolecules such as peptides, which have inher-
ently low oral bioavailability. In the present study, the safety of a
novel OS formulation of the octapeptide octreotide was dem-
onstrated in a monkey chronic toxicity study. OS permeation
activity characterized in rats shows that OS transiently en-
hances permeability via paracellular transport in the small and
large intestines. The OS was shown to affect distribution of the
tight junction protein, ZO-1 in rat intestine. Enteral dosing of
octreotide acetate formulated in OS to rats also resulted in
systemic octreotide exposure and significantly attenuated plas-
ma GH levels, demonstrating that octreotide retained its bio-
logical inhibitory activity.
The safety of octreotide acetate formulated with OS was
demonstrated by the lack of clinical or laboratory evidence of
adverse findings in monkeys after daily oral administration of
enteric-coated capsules for nine months. Importantly, adverse
macroscopic or microscopic findings were not detected in the
gastrointestinal tract or liver in the toxicology study. These
observations are also in agreement with the tolerance to oral
octreotide acetate formulated in OS in a series of Phase 1
studies in healthy subjects (18).
The rat studies reported herein showed that OS perme-
ation enhancement is accompanied by reorganization of tight
junction proteins ZO-1 and claudin-3, and with diffusion of
LC-biotin between enterocytes. Paracellular transport via the
Fig. 6 Paracellular permeability effect of the oily suspension formulation. To visualize the paracellular flux, sulfo-NHS-LC-biotin was added as a tracer to saline or
oily suspension (OS). These preparations were then administered under anesthesia to the jejunum of SD rats (n=3, each). Upon administration of LC-biotin
tracer to the intestinal cells it is expected that the tracer staining will represent the intestinal permeation, inasmuch as that restricted permeation via the intestinal
epithelium will present only staining on the mucosal layer whereas increased intestinal permeability will be translated into staining pattern that encompass also the
basolateral membranes [see illustration in the upper panel (a)]. The lower panel images show the biotinylated tracer distribution (blue) by confocal microscopy in
saline (b) and OS (c) treated rats. Arrows show the tracer permeated through the paracellular route in the OS but not the saline-treated rats. Lateral membranes
are marked in redby actin and purple (overlay blue and red) indicates regions that the LC-biotin tracer penetrated between two adjacent epithelial cells. Scale bars
represent 50 μm.
Table I Plasma Octreotide Levels of Cynomoglus Monkeys Orally Dosed
for 9-months with 20 mg Octreotide Acetate and Oily Suspension in Enteric-
coated Capsules
Sex PK parameters Treatment days
1 180 270
Male Cmax (ng/mL) 22±6 39±35 30±18
AUC0-t (h×ng/mL) 49±13 84±74 68±40
Female Cmax (ng/mL) 15±4 13±3 42±14
AUC0-t (h×ng/mL) 34±9 28±7 92±31
Total Cmax (ng/mL) 19±4 26±13 36±11
AUC0-t (h×ng/mL) 42±8 56±29 80±25
Results expressed as arithmetic mean ± SE (n=5 per gender)
2018 Tuvia et al.
tight junction is physiologically regulated by intracellular sig-
naling [See review in (22)]. Extracellular stimuli, including
dietary components, drugs, and chemicals, alter paracellular
transport (9). In the OS formulation, the key permeation
enhancement excipient is sodium caprylate. The mechanism
by which sodium caprylate affects the intestinal cells is not fully
elucidated; however, the mechanism has been extensively
studied for other members of MCFAS, such as sodium
caprate. Lindmark and colleagues reported (23) that in
Caco-2 cells, sodium caprate increased paracellular transport
via contraction of actin filaments following phosphorylation of
myosin light chains (MLC) by Ca2+/calmodulin-activated
MLC kinase. Using this cell assay, others (24–26) have shown
that tight junction dilatation following sodium caprate dosing
was accompanied by altered localization of ZO-1, occluding,
claudin-1 and F-actin. Kurasawa and colleagues (27) also
reported that in human epidermal keratinocytes sodium
caprate induced reversible redistribution of tight junction pro-
teins, which was also associated with diffusion of LC-biotin
via occluding-positive sites. Results shown here demonstrate
for the first time effects of MCFAS in vivo on localization of
tight junction proteins and the facilitation of paracellular pen-
etration across the rat intestine.
To further characterize the permeation enhancement ef-
fect of OS, fluorescently labeled dextrans of known molecular
sizes were formulated in OS and tested in vivo in rats. Dextrans
were employed as marker molecules as they do not penetrate
the intestinal wall nor are they metabolized (28,29). The FD4
permeation effect of OS was comparable between intestinal
segments, but was limited following gavage administration.
The latter finding, i.e. poor gastric FD4 absorption, may be
associated with (i) effects of stomach acidity on the OS formu-
lation, i.e. hydrolysis of the sodium caprylate to caprylic acid
and so on for other excipients in the OS and/or (ii) limited OS
permeation effect on gastric mucosa. These observations sup-
port the use of enteric-coated capsules for optimal intestinal
permeation effect of the OS, i.e. to allow the OS to reach the
small intestines without deterioration. Induced OS perme-
ation effect was shown to be transient, non-refractory and
reversible returning to baseline at about 1 h post dosing. In
addition, the enhancing effect of OS was dose-proportional
and molecular size-dependent. Absorption of fluorescent mol-
ecules decreased with increasing molecular weight from 4 to
40 kDa with only limited absorption occurring with 70 kDa
dextran. Increased permeability was temporal, as demonstrat-
ed by decreased absorption of FD4 within 10 min after OS
dosing. Intestinal permeability returned to basal levels approx-
imately 1–1.5 h after OS dosing in rats. Taken together, the
OS-induced intestinal permeation effect exhibits molecular
size, spatial and temporal constraints.
The induced MCFAS permeation mechanism have raised
safety concerns (10) for intestinal absorption of a gastrointes-
tinal “bystander” pathogen. Current data in the literature
would suggest the notion that increased intestinal permeability
is insufficient to cause disease in an otherwise normal individ-
ual [See review in ref. (30)]. Moreover, transgenic mice with
Fig. 7 Enteral administration of octreotide formulated in oily suspension
inhibits rat growth hormone levels. (a) Octreotide plasma concentration-time
profiles after enteral administration of octreotide (3.2 mg/kg) formulated with
oily suspension (OS) or after subcutaneous (SC) injection of octreotide acetate
(0.172 mg/kg) in saline solution to cannulated rats (Mean ± SE; n=5–12). (b)
Maximum changes in the concentrations (Cmax; circles) and area-under-the-
curve (AUC0-t; squares) of plasma octreotide after intra-jejunal administration
of octreotide/OS formulation to male SD rats at increasing concentrations
(Data are means ± SE; n=9–1)]. (c) The effect of a single enteral adminis-
tration (arrow) of saline (circles) or octreotide/OS (triangles) on growth hor-
mones (GH) was evaluated in conscious SD rats. Blood was collected via
jugular vein for GH analysis 30-min prior to dosing and up to 3.5 h post-
dosing. In addition, octreotide concentrations (squares) were measured in
plasma samples up to 90min using ELISA assay (See text for details). Measured
GH in the octreotide/OS-treated group were considerably lowered
(P<0.001) compared with the saline-dosed group and the pre-treatment
levels (P<0.001). Data are means ± SE (n=10).
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increased intestinal permeability or reduced intestinal barrier
functions, exhibiting isolated intestinal epithelial tight junction
barrier defects did not lead to spontaneous disease (31,32).
These animal models suggest that the transient increase in
epithelial permeability, such as resulting from tight junction
regulation following OS administration, will not be pathogen-
ic in an otherwise healthy host. This concept is further sup-
ported by the results shown here for the octreotide/OS safety
in monkeys. In addition, the presented rat data suggests that
the OS-induced permeation mechanism may prevent unde-
sired absorption of pathogens residing in the intestines, which
are typically ≥70 kDa.
Oral octreotide absorption from octreotide/OS in enteric-
coated capsules was confirmed by toxicokinetic measurements
in monkeys. Systemic exposure to octreotide was shown to be
comparable between males and females and consistent,
though variable, over the study period. These findings are in
agreement with a previous report of administration of oral
octreotide formulated with OS in enteric-coated capsules to
healthy human subjects (18). Enteral octreotide acetate ab-
sorption enhanced in a concentration-dependent manner,
when formulated with OS and administered to rats. In
contrast, limited enteral octreotide absorption occurred
in the absence of OS formulation, as previously shown
by others (33–37). Effects of systemic octreotide expo-
sure have been observed in cannulated rats. Rats dosed
with octreotide/OS formula exhibited suppressed GH
levels for >3 h post-dosing, whilst circulating GH con-
centrations in the control group were unaffected. These
observations are consistent with the reported octreotide
effect, i.e. binding to pituitary somatostatin receptors 2, 3, and
5 and markedly reducing GH secretion for several hours (38).
Taken together, these results indicate that formulating
octreotide with OS enables enteral absorption while main-
taining potent somatostatin analog bioactivity in suppressing
GH concentrations.
In conclusion, this study shows that daily oral administra-
tion of an octreotide/OS formulation for up to 9 months
resulted in measurable plasma drug levels with minor
treatment-related findings that were comparable to the
octreotide injection. These results also demonstrate the feasi-
bility of drug delivery using the OS in conjunction with
hydrophilic macromolecules based upon permeation en-
hancer characteristics. A specific formulation of
octreotide/OS is currently in a clinical study to evaluate
the safety and efficacy of oral somatostatin analogue
therapy in acromegaly patients.
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